Molecular Diagnostics

Similar documents
Fully Integrated DNA Amplification Devices for Infectious Disease Diagnosis

Point-of-care multiplexed molecular amplification and visual detection for HIV- 1 and beta-actin without electricity

Detect TB. Accurately. Easily.

How best to structure a laboratory network with new technologies

Next Generation TB Diagnostics An Update from BMGF. Lee Pyne-Mercier

Diagnostics: Bench to Bedside Pathway

Alere Technologies GmbH

- UPDATE - Implementation and roll-out of Xpert MTB/RIF October 2011

Clinical and Public Health Impact of Nucleic Acid Amplification Tests (NAATs) for Tuberculosis

African Society for Laboratory Medicine

AN ACTIVIST S GUIDE TO. Tuberculosis Diagnostic Tools

Xpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it

POSITIONING OF TB DX : TIERED SYSTEM, INTEGRATED APPROACH

NAAT in the Clinical Laboratory and Impact on Infection Control 9 th National Conference on Laboratory Aspects of Tuberculosis APHL

Nucleic Acid Amplification Test for Tuberculosis. Heidi Behm, RN, MPH Acting TB Controller HIV/STD/TB Program Oregon, Department of Health Services

WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: Alere q HIV-1/2 Detect WHO reference number: PQDx

CULTURE OR PCR WHAT IS

Balancing investment in point of care diagnostics versus laboratory testing in low resource settings. June 28, 2011

Stacy White, PhD May 12, TB for Community Providers. Phoenix, Arizona

Ken Jost, BA, has the following disclosures to make:

Research Methods for TB Diagnostics. Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012

National Xpert MTB/RIF Programme

New Generation of Nucleic Acid Testing. Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention

The Application of molecular POCT for Influenza and Group A Strep Detection

Xpert MTB/RIF Training. Indira Soundiram 2012

Receipt within 1 day of specimen collection. Report AFB b smear result within 1 day from receipt of specimen

Original Article Evaluation of Xpert MTB/RIF in detection of pulmonary and extrapulmonary tuberculosis cases in China

Alere q A Molecular Platform for Global Health Diagnostics

TB FIT Modelling. 24th Annual PhilCAT Convention. Ivor Langley and Ewan Tomeny Liverpool School of Tropical Medicine AUGUST 2017

American Association for Clinical Chemistry Emerging Clinical & Laboratory Diagnostics: The Portable Lab April 24-25, 2014

Xpert MTB/RIF use for TB diagnosis in TB suspects with no significant risk of drug resistance or HIV infection. Results of Group Work

TB Laboratory for Nurses

CDPH - CTCA Joint Guidelines Guideline for Micobacteriology Services In California

TB Diagnostics: Global Market Analysis and Potential

TB NAAT testing at the Los Angeles County Public Health Laboratory

Virtual Implementation Evaluation of Tuberculosis diagnostics in Tanzania Ivor Langley, Liverpool School of Tropical Medicine

2018 Tuberculosis Clinical Intensive: Infection Prevention & Control. > No disclosures

Point of Care Tests for respiratory viruses: impact on clinical outcomes of patients

Grant Summary Report: Expansion of Nucleic Acid Amplification Testing for TB In Public Health Laboratories

TB Intensive San Antonio, Texas November 11 14, 2014

Update on LAMP Project. OFFLU Technical Meeting, 4-5 April 2012 Royal Holloway, UK Sasan Fereidouni, Anja Globig

of clinical laboratory diagnosis in Extra-pulmonary Tuberculosis

Diagnostic challenges of active childhood TB in Tanzania. Michala Vaaben Rose, MD, Ph.D Department of Infectious Diseases, Hvidovre

Innovations in nucleic acid amplification technologies. Automated platforms for NAT. Microfluidics Digital PCR Innovations in nucleic acid microarrays

Rapid PCR TB Testing Results in 68.5% Reduction in Unnecessary Isolation Days in Smear Positive Patients.

Point of Care (POC) diagnostics for microbial infections and POC susceptibility measurements: The need in Indian context. Dr.

New Standards for an Old Disease:

Overview of Mycobacterial Culture, Identification, and Drug Susceptibility Testing

AMPLIRUN TOTAL A RELIABLE QUALITY CONTROL SOURCE FOR NUCLEIC ACID TESTS

Towards Harmonization of Mycobacteriology in TB Trials. Study 31/ACTG 5349 Key Elements of Mycobacteriology Laboratory Procedures

Health Care Worker Training on Roll Out New TB Diagnostic Test. Prepared by: City Health (J Caldwell) & NHLS (M Bosman & I Noordien)

Planning for the implementation of new diagnostic tests

Progress Report March 2016

Diagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014

Use of the Cepheid GeneXpert to Release Patients from Airborne Isolation

Implementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of tuberculosis and multidrug-resistance GLOBAL CONSULTATION

Report of TB/HIV Diagnostics Task Force. Barbara Laughon NIAID, NIH

Treating Patients, Not Disease: People-Centered Approach

Update on CD4+ T-Cell Counting Technologies

Diagnosis of Tuberculosis by GeneXpert MTB/RIF Assay Technology: A Short Review

TB: A Supplement to GP CLINICS

Liquid Biopsy Applications on the Idylla Fully Integrated Sample-to-Result MDx System

Diagnosis of HIV-Associated Tuberculosis

GeneXpert HIV-1 Quantitative assay Natasha Samsunder

Principle of Tuberculosis Control. CHIANG Chen-Yuan MD, MPH, DrPhilos

Costs of Novel Tuberculosis Diagnostics Will Countries Be Able to Afford It?

Point-of Care Technology:

Rapid Diagnostics CHAI Experience. 6 th Moving Forward in Diagnostics Forum Les Pensieres November 7, 2012

Diagnostics in a Digital Age: Promises and Challenges

Implementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB. Global Consultation

Role of subclinical TB: Can we model prevention of TB in the subclinical stages?

Diagnosis of drug resistant TB

Utility of HCV antigen core quantification for the screening of chronic hepatitis C

New frontiers: Innovation and Access

AUTOMATED REAL-TIME NUCLEIC ACID AMPLIFICATION TECHNOLOGY FOR RAPID AND SIMULTANEOUS DETECTION OF TUBERCULOSIS AND RIFAMPICIN RESISTANCE:

INTENSIFIED TB CASE FINDING

Diagnosis of Extra Pulmonary Tuberculosis By Using Xpert MTB/RIF Assay (CBNAAT) And MGIT Liquid Culture.

The MycoDDR Product Line is Essential for Mycobacteria Survival and Recovery

Laboratory Diagnostic Techniques. Hugo Donaldson Consultant Microbiologist Imperial College Healthcare NHS Trust

Portable PCR for early detection and rapid response to avian influenza

World Journal of Pharmaceutical and Life Sciences WJPLS

DNA amplification and detection using a ph-sensing system:

Report on WHO Policy Statements

10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose

Diagnosing Xpert MTB/RIF negative TB suspects: Impact and cost of an alternative algorithm

Identifying TB co-infection : new approaches?

Modelling Innovative Diagnostic Tools for Tuberculosis

Diagnosis of TB: Laboratory Ken Jost Tuesday April 9, 2013

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016

EXPERT GROUP MEETING REPORT

TB 101 Disease, Clinical Assessment and Lab Testing

Cepheid The MDx Growth Leader. William Blair Growth Stock Conference June 12, 2012

Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf

AFB Identification Texas Approach

Point of care testing for respiratory viruses

TB & HIV CO-INFECTION IN CHILDREN. Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012

The 1 st National TB Prevalence Survey Nigeria 2012

New Tuberculosis Guidelines. Jason Stout, MD, MHS

NATIONAL TUBERCULOSIS PREVALENCE SURVEY 2016

Molecular diagnosis of infectious disease - Method validation and environmental setting 傳染病的分子診斷 - 方法確認與環境背景. WC Yam 任永昌

Transcription:

Fully Integrated DNA Amplification Devices for Infectious Disease Diagnosis Angelika Niemz, Keck Graduate Institute, Claremont, CA AACC Emerging Technologies for Clinical & Laboratory Diagnostics San Jose, CA April 24-25, 2014 Molecular Diagnostics Traditionally restricted to high complexity laboratories Physical space separated from the main clinical laboratory Typically separate rooms for preamplification steps (nucleic acid extraction, reaction setup), and amplification / post-amplification steps Move towards moderate complexity integrated systems that can be used in regular clinical laboratory settings Extract Nucleic Acids Set up Reaction (Master-Mix) Amplify and Detect Smaller Fully Integrated PCR-Based Systems Cepheid: GeneXpert IdahoTech: FilmArray Iquum: LIAT Alere: Alere Q Luminex: Aries Biocartis: Idylla Enigma: Mini-Laboratory 3 Molecular Diagnostics: Current Research and Applications (Chapter 10), Horizon Press, 2014 1

Systems based on Isothermal Amplification Automated, Integrated Sample Preparation, Amplification & Detection Great Basin: Portrait Analyzer Alere: Alere i Manual Sample Prep, Automated Amplification & Detection Meridian: Illumigene TwistDx: Twista Optigene: Genie Lumora: BART Manual Sample Prep, Amplif. & Detection Biohelix: IsoAmp Ustar: EasyNAT Molecular Diagnostics: Current Research and Applications (Chapter 10), Horizon Press, 2014 4 Disseminated Nucleic Acid Testing Driving Factors: Time to result: Ability to test and treat / contain disease Accessibility: Is central laboratory network available? Affordability: Cost of consumables and instrument Clinical performance: Results equivalent to reference method Operator skills: Required training, potential for user error Infrastructure: Power, refrigeration, other equipment Key Applications: Developed Countries: Hospital acquired infections Influenza / Respiratory Pathogens Developing Countries: HIV viral load testing / infant diagnosis TB diagnosis / drug resistance testing 5 Tuberculosis Estimated TB Incidence Rate for 2012 Leading cause of death from a curable infectious disease in 2012: 8.6 million incident cases, 1.3 million deaths Diagnostic methods for active TB: Sputum smear microscopy Chest X-ray Culture-based methods Nucleic Acid Testing Advantages: Faster than culture, high sensitivity and specificity Disadvantages: Complexity, Cost Source: WHO TB Report 2013 AFB Microscopy BD MGIT TB Culture Sputum Sample Mycobacterium tuberculosis 6 2

Cepheid GeneXpert MTB/RIF 7 N. Engl. J. Med. 2010, 363, 1005-1015 GeneXpert MTB/RIF: Global Roll-Out 8 http://who.int/tb/laboratory/mtbrifrollout/en/ GeneXpert MTB/RIF: Pros and Cons Pros: Enables TB diagnosis and rifampin resistance testing in < 2 hours Suitable for low-skilled users, contamination controlled Recommended for district and sub-district level laboratories Cons: Expensive: Discount pricing for public sector labs in eligible countries: Instrument ($17,500), cartridge ($9.98), calibration ($ 1,800 per year) Requires uninterrupted line power, external computer Operating temperatures 30 C, cartridge storage 2-28 C, cartridges guaranteed shelf life of 6-9 months Internet linkage recommended for external QC and result recording unsuitable for low resource peripheral settings that serve the majority of affected patients 9 Consequence: patient not diagnosed or lost to follow-up after initial diagnosis 3

Addressing User Needs: Peripheral Microscopy Centers in High TB Burden Countries Implementing TB NAT in peripheral microscopy centers identified as high priority by key stakeholders Typically associated with primary health care facilities that can initiate and administer TB treatment Possibility to test and treat in the same clinical encounter Currently, 42,827 microscopy centers in the public sector of the 22 high TB burden countries perform ~ 77.6 million sputum smear tests annually Nucleic acid testing as replacement for sputum smear microscopy for initial TB diagnosis: estimated market potential ~ 30.8 million tests annually 10 Expert Rev. Mol. Diagn. 2013, 13, 763 767 Eur Respir J. 2014 Feb 13. [Epub ahead of print] Addressing User Needs: Peripheral Microscopy Centers in High TB Burden Countries 11 Expert Rev. Mol. Diagn. 2013, 13, 763 767 Other Molecular Diagnostics Systems for TB Diagnosis PCR based systems with real time fluorescence detection MolBio: TrueLab Uno MTB Epistem: Genedrive Tuberculosis Systems based on isothermal DNA amplification Eiken: LoopAmp TB Ustar: EasyNAT TB In Development: AlereQ 12 Exp. Rev. Mol. Diagn. 2012, 12, 687 4

TB NAT systems: Suitable for Low Resource Settings? Sample Prep Amplification Detection Cost GeneXpert automated and integrated sample prep + qpcr high Alere Q automated and integrated sample prep + NEAR high TrueLab semiautomated automated / integrated qpcr medium GeneDrive manual automated / integrated qpcr medium LoopAmp manual automated (LAMP) manual (visual fluorescence) low EasyNAT manual heat bath (CPA) manual (NALF cassette) low 13 Exp. Rev. Mol. Diagn. 2012, 12, 687 Eiken LoopAmp MTBC Detection test 14 Int J Tuberc Lung Disease 2011, 15, 1211 1217 USTAR: EasyNAT TB Diagnostic kit 15 USTAR EasyNAT Package Insert 5

Our Goal Cepheid: GeneXpert Current Device Prototype Enable diagnosis of pulmonary tuberculosis in microscopy centers of high burden countries by developing a portable, easy to use, integrated nucleic acid testing device that provides a result in < 1.5 h sample-in-toanswer-out, at a significantly lower cost than currently available fully integrated bench-top nucleic acid testing systems. The device shall be battery operated, with all reagents on board in a thermo-stable form. 16 Current Status Sample in Answer out 17 Developed POC compatible processes for: Sputum liquefaction and disinfection, pathogen lysis / nucleic acid extraction Isothermal Loop-Mediated Amplification (LAMP) using thermo-stable mastermix, coupled to lateral flow detection Device design and integration: Developed a prototype integrated cartridge and compact instrument Demonstrated process execution in a fully automated manner, following introduction of liquefied and disinfected sputum into the cartridge Disclaimer The remainder of this presentation has been removed for inclusion in the online course manual, since it contains proprietary or unpublished data. This material will be reinserted for the actual live presentation. 18 6

Acknowledgements Angelika Niemz, Hsiang-Wei Lu, Anna Hickerson, Supriya Kadam, Pranav Kumar, Ilya Tolstorukov, Eric Houghton, Catherine Lee, Kristina Roskos, Tomas Carey, Peter Vandeventer, et al. Gerard Cangelosi, Kris Weigl, Annie Lakey, Kelly Jones David Boyle, Bernhard Weigl, Scott Priddy et al. Masa Narita, Dorothy Gibson, Sergio Steele, Megan Savlov Robert Doebler, Tanya Ferguson, Keith Herrington, Ryan Talbot, et al. Murray Learmonth, Joseph Donoghue Delia Ontengco 19 Funding: NIH-NIAID R01AI076247 and R01AI090831 7